Alnylam to Report New Clinical Results with Fitusiran at the World Federation of Hemophilia (WFH) 2016 World Congress
July 25 2016 - 8:00AM
Business Wire
– New Phase 1 Results to Include Initial Data
in Hemophilia A and B Patients with Inhibitors –
– Company to Host Conference Call on Wednesday,
July 27, 2016, at 1:00 p.m. ET to Discuss Results –
Alnylam Pharmaceuticals, Inc.
(Nasdaq:ALNY), the leading RNAi therapeutics company, announced
today that Alnylam and collaborators will present interim results
from the ongoing Phase 1 clinical trial with fitusiran, an
investigational RNAi therapeutic targeting antithrombin (AT) for
the treatment of hemophilia A and B and rare bleeding disorders
(RBD) at the World Federation of Hemophilia (WFH) 2016 World
Congress being held July 24 – 28, 2016 in Orlando, Florida.
The data will be presented in an oral presentation titled “A
Subcutaneously Administered Investigational RNAi Therapeutic,
Fitusiran (ALN- AT3), Targeting Antithrombin for Treatment of
Hemophilia: Interim Results in Patients with Hemophilia A or B” by
lead author John Pasi, MB, ChB, Ph.D., FRCP, FRCPath, FRCPCH,
Professor of Haemostasis and Thrombosis and Consultant
Haemotologist at Barts Health NHS Trust. The presentation will take
place on Wednesday, July 27, 2016, at 11:30 a.m. ET, in Room
206.
Alnylam will host a webcast conference call on Wednesday, July
27, 2016 at 1:00 p.m. ET to discuss these results. A slide
presentation will also be available on the Investors page of the
company's website, www.alnylam.com, to accompany the conference
call. To access the call, please dial 877-312-7507 (domestic) or
631-813-4828 (international) five minutes prior to the start time
and refer to conference ID 51834298. A replay of the call will be
available beginning at 4:00 p.m. ET on July 27, 2016. To access the
replay, please dial 855-859-2056 (domestic) or 404-537-3406
(international), and refer to conference ID 51834298. In addition,
an archived webcast will be available on the Alnylam website
approximately two hours after the event.
Finally, Alnylam will also host an investor reception to discuss
the new fitusiran clinical results on Wednesday, July 27, 2016 from
5:30 – 6:30 p.m. ET at the Rosen Plaza Hotel in Orlando.
About Alnylam Pharmaceuticals
Alnylam is a biopharmaceutical company developing novel
therapeutics based on RNA interference, or RNAi. The company is
leading the translation of RNAi as a new class of innovative
medicines. Alnylam’s pipeline of investigational RNAi therapeutics
is focused in 3 Strategic Therapeutic Areas (STArs): Genetic
Medicines, with a broad pipeline of RNAi therapeutics for the
treatment of rare diseases; Cardio-Metabolic Disease, with a
pipeline of RNAi therapeutics toward genetically validated,
liver-expressed disease targets for unmet needs in cardiovascular
and metabolic diseases; and Hepatic Infectious Disease, with a
pipeline of RNAi therapeutics that address the major global health
challenges of hepatic infectious diseases. In early 2015, Alnylam
launched its “Alnylam 2020” guidance for the advancement and
commercialization of RNAi therapeutics as a whole new class of
innovative medicines. Specifically, by the end of 2020, Alnylam
expects to achieve a company profile with 3 marketed products, 10
RNAi therapeutic clinical programs – including 4 in late stages of
development – across its 3 STArs. The company’s demonstrated
commitment to RNAi therapeutics has enabled it to form major
alliances with leading companies including Merck, Medtronic,
Novartis, Biogen, Roche, Takeda, Kyowa Hakko Kirin, Cubist,
GlaxoSmithKline, Ascletis, Monsanto, The Medicines Company, and
Sanofi Genzyme. In addition, Alnylam holds an equity position in
Regulus Therapeutics Inc., a company focused on discovery,
development, and commercialization of microRNA therapeutics.
Alnylam scientists and collaborators have published their research
on RNAi therapeutics in over 200 peer-reviewed papers, including
many in the world’s top scientific journals such as Nature, Nature
Medicine, Nature Biotechnology, Cell, New England Journal of
Medicine, and The Lancet. Founded in 2002, Alnylam maintains
headquarters in Cambridge, Massachusetts. For more information
about Alnylam’s pipeline of investigational RNAi therapeutics,
please visit www.alnylam.com.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160725005579/en/
Alnylam Pharmaceuticals, Inc.(Investors and
Media)Christine Regan Lindenboom, 617-682-4340or(Investors)Josh
Brodsky, 617-551-8276
Alnylam Pharmaceuticals (NASDAQ:ALNY)
Historical Stock Chart
From Mar 2024 to Apr 2024
Alnylam Pharmaceuticals (NASDAQ:ALNY)
Historical Stock Chart
From Apr 2023 to Apr 2024